Sentence: Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy ( TANIA ): an open-label , randomised phase 3 trial .
Drug combination annotation:
[{'class': 'POS', 'spans': ['bevacizumab', 'TANIA'], 'is_context_needed': True}]